GW Pharmaceuticals (GW Pharma) is a UK based pharmaceutical company that is pioneering research and development of the potential therapeutic applications of cannabinoids and the endocannabinoid system across a wide range of diseases.
They are currently developing a portfolio of cannabinoid medicines which includes Sativex® for the treatment of multiple sclerosis(MS) spasticity, and Epidiolex® for the treatment of childhood epilepsy.
They also hold a patent on phytocannabinoids for the treatment of cancer.
Our vision… is to be the global leaders in prescription cannabinoid medicines, through the rapid cost-effective development of pharmaceutical products which address clear unmet needs… – courtesy of gwpharma.com
GW Pharmaceuticals takes the production of their medicine seriously. From beginning to end, they have their process down to a strict science. They rely on rotary evaporators to help them in their mission to produce clean, cost-effective medicine.
Check out rotovaps in action during the production of Sativex® at GW Pharma’s lab in this clip from a BBC documentary (note – make sure to watch the whole clip to get a great insider’s look at the whole production process).
Across International also carries a line of laboratory-grade rotovaps that are used by many extracts labs like AI Fam The Cannabissary Dab Lab to produce clean medicine.
Sativex® Cannabis Spasticity Treatment
GW Pharma’s lead product, Sativex®, is the world’s first legal cannabis-based medicine and is now approved in 27 countries.
This cannabinoid medicine comes as an oral spray and is specifically used for the treatment of spasticity due to multiple sclerosis.
Here’s what GW Pharma’s website, says about Sativex®:
…is indicated as a treatment for symptom improvement in patients with moderate to severe spasticity due to multiple sclerosis who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.
Sativex® is now also in Phase III clinical development for the treatment of cancer pain, the lead indication for the US market.
Epidiolex® Cannabis Treatment for Pediatric Epilepsy
Epidiolex® is a cannabinoid medicine used for the treatment of childhood epilepsy. Epidiolex® is still in the trial stages and, according to GW Pharma’s website, will initially be focused on treating two orphan indication syndromes of epilepsy – Dravet Syndrome and Lennox-Gastaut Syndrome.
Our strategy for the development of Epidiolex in pediatric epilepsy is to initially concentrate on two orphan indication syndromes – Dravet Syndrome and Lennox-Gastaut Syndrome. We expect to further expand the market opportunity by either targeting additional orphan seizure disorders and/or by seeking approval for a wider indication of pediatric epilepsy refractory to current treatments.
Make sure you visit the official GW Pharmaceuticals website for information on the company, their current protfolio of cannabinoid medicines, and their contact information.